Processa Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Processa Pharmaceuticals, Inc. on November 3, 2021. The report details the results of a Special Meeting of stockholders held on September 13, 2021, regarding corporate governance and capital structure amendments.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on stockholder voting outcomes and does not contain financial performance data.
Material Changes and Voting Results
Stockholders voted on two proposals at the Special Meeting. A total of 15,604,605 shares were entitled to vote, with 11,042,376 shares present in person or by proxy.
- Proposal 1: Approval of an amendment to the Fourth Amended and Restated Certificate of Incorporation to increase authorized common stock from 30,000,000 to 50,000,000 shares.
- For: 10,857,914
- Against: 183,334
- Abstain: 1,128
- Broker Non-Votes: 0
- Proposal 2: Approval of an adjournment of the Special Meeting if necessary to solicit additional proxies for Proposal 1.
- For: 10,785,919
- Against: 249,851
- Abstain: 6,606
- Broker Non-Votes: 0
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management commentary on financial outlook, specific risks, contingencies, or unusual items beyond the voting results.
Key Facts for Investor Verification
- Stockholders approved increasing the authorized share count to 50,000,000 shares.
- Both proposals passed with overwhelming support (over 98% of votes cast were in favor).
- The filing contains no financial performance data; investors should refer to the most recent 10-K or 10-Q for financial metrics.
- The record date for the vote was September 13, 2021.